# Collegium Pharmaceutical, Inc.

Type: Company (COLL)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/collegium-pharmaceutical-inc
Canonical HTML page: https://getfinancebrief.com/entity/collegium-pharmaceutical-inc

## Timeline

- **2026-03-15**: Eventide Rebalancing — Eventide Asset Management reports a reduced but significant stake of $83.65 million in Collegium.
- **2026-03-06**: Institutional Reduction — Integrated Quantitative Investments LLC reduces its stock position in COLL.
- **2026-02-18**: Truist Analysis — Truist Securities highlights momentum for Jornay PM and a robust pain portfolio.
- **2022-03-22**: BDSI Acquisition — Collegium completes the acquisition of BioDelivery Sciences International, adding Belbuca to its portfolio.

## Recent coverage (2 stories)

### Eventide Asset Management Trims Stake in Collegium Pharmaceutical to $83.6M
2026-03-15 12:47:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Eventide Asset Management LLC has reduced its equity position in Collegium Pharmaceutical, Inc. (COLL), though it maintains a significant $83.65 million stake. This institutional shift comes as the specialty pharmaceutical firm navigates a shifting landscape for chronic pain management and expands into neurology.
Full story: https://getfinancebrief.com/story/eventide-reduces-collegium-pharmaceutical-stake

### CRA International and Collegium Pharma Signal Resilience in Q4 2025 Results
2026-02-27 14:49:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.
Full story: https://getfinancebrief.com/story/crai-coll-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.